Q3 2024 13F Holders as of 9/30/2024
-
Type / Class
-
Equity / Class A Common Stock
-
Shares outstanding
-
13.2M
-
Number of holders
-
28
-
Total 13F shares, excl. options
-
6.66M
-
Shares change
-
+5.89M
-
Total reported value, excl. options
-
$63.2M
-
Value change
-
+$55.9M
-
Number of buys
-
12
-
Number of sells
-
-3
-
Price
-
$9.50
Significant Holders of Avalo Therapeutics, Inc. - Class A Common Stock (AVTX) as of Q3 2024
30 filings reported holding AVTX - Avalo Therapeutics, Inc. - Class A Common Stock as of Q3 2024.
Avalo Therapeutics, Inc. - Class A Common Stock (AVTX) has 28 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 6.66M shares
of 13.2M outstanding shares and own 50.6% of the company stock.
Largest 10 shareholders include Ikarian Capital, LLC (970K shares), RA CAPITAL MANAGEMENT, L.P. (967K shares), Deep Track Capital, LP (967K shares), BVF INC/IL (967K shares), ORBIMED ADVISORS LLC (967K shares), Logos Global Management LP (539K shares), COMMODORE CAPITAL LP (483K shares), TCG Crossover Management, LLC (483K shares), BOOTHBAY FUND MANAGEMENT, LLC (164K shares), and Sio Capital Management, LLC (71.5K shares).
This table shows the top 28 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.